IDEXX Laboratories, Inc. IDXX is well-poised to grow in the upcoming quarters due to the strong momentum in its CAG (Companion Animal Group) Diagnostics business. The company is also growing its ...

Fundsmith, an investment management firm based in London, has released its annual 2025 investor letter for its “Fundsmith Equity Fund.” A copy of the letter can be downloaded here. The fund focuses on ...

Achieves third quarter revenue growth of 7% as reported and 6% organic, supported by CAG Diagnostics recurring revenue growth of 7% as reported and organic. Organic revenue growth supported by ...

Achieves first quarter revenue growth of 4% as reported and 5% organic, supported by CAG Diagnostics recurring revenue growth of 3% as reported and 4.5% organic. Organic revenue growth supported by ...

Image quality comparison between ImageVue DR50 and ImageVue DR50 Plus Radiography is a standard diagnostic technique in ...

In the latest quarter, 4 analysts provided ratings for IDEXX Laboratories (NASDAQ:IDXX), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, ...

While they might not represent the most exciting field in the biotech space, animal healthcare companies have been a steady, consistent source of growth in what's often a turbulent market. One company ...

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 fourth quarter and full year financial results for Monday, February 2, 2026 ...

Since joining IDEXX in 2011, he has held senior positions across key portions of the Company's business, including ...

IDEXX Laboratories has designated Michael Erickson to succeed Jonathan Mazelsky at the helm of the pet healthcare company later this year.

The IDEXX Cancer Dx Panel has already transformed cancer screening for veterinarians. Today, more than 5,500 practices across ...